AB68,1560,10 (b) Public outreach. 1. The commissioner shall conduct public outreach to create awareness of the urgent need safety net programs and patient assistance programs.

AB68,1560,12 2. The commissioner shall develop and make available on the office's Internet site an information sheet that contains all of the following information:

AB68,1560,14 a. A description of how to access insulin through an urgent need safety net program.

AB68,1560,15 b. A description of how to access insulin through a patient assistance program.

AB68,1560,17 c. Information on how to contact a navigator for assistance in accessing insulin through an urgent need safety net program or patient assistance program.

AB68,1560,19 d. Information on how to contact the commissioner if a manufacturer determines that an individual is not eligible for a patient assistance program.

AB68,1560,21 e. A notification that an individual may contact the commissioner for more information or assistance in accessing ongoing affordable insulin options.

AB68,1561,3 (c) Navigators. The commissioner shall develop a training program to provide navigators with information and the resources necessary to assist individuals in accessing appropriate long-term insulin options. The commissioner shall compile a list of navigators who have completed the training program and are available to assist individuals in accessing affordable insulin coverage options. The list shall be made available on the office's Internet site and to pharmacies and health care practitioners who dispense and prescribe insulin.

AB68,1561,9 (d) Satisfaction surveys. 1. The commissioner shall develop and conduct a satisfaction survey of individuals who have accessed insulin through urgent need safety net programs and patient assistance programs. The survey shall ask whether the individual is still in need of a long-term solution for affordable insulin and shall include questions about the individual's satisfaction with all of the following, if applicable:

AB68,1561,10 a. Accessibility to urgent-need insulin.

AB68,1561,12 b. Adequacy of the information sheet and list of navigators received from the pharmacy.

AB68,1561,13 c. Helpfulness of a navigator.

AB68,1561,15 d. Ease of access in applying for a patient assistance program and receiving insulin from the pharmacy under the program.

AB68,1561,19 2. The commissioner shall develop and conduct a satisfaction survey of pharmacies that have dispensed insulin through urgent need safety net programs and patient assistance programs. The survey shall include questions about the pharmacy's satisfaction with all of the following, if applicable:

AB68,1561,21 a. Timeliness of reimbursement from manufacturers for insulin dispensed by the pharmacy under urgent need safety net programs.

AB68,1561,22 b. Ease in submitting insulin orders to manufacturers.

AB68,1561,23 c. Timeliness of receiving insulin orders from manufacturers.

AB68,1561,25 3. The commissioner may contract with a nonprofit entity to develop and conduct the surveys under subds. 1. and 2. and to evaluate the survey results.

AB68,1562,3 4. No later than July 1, 2024, the commissioner shall submit to the governor and the chief clerk of each house of the legislature, for distribution to the legislature under s. 13.172 (2), a report on the results of the surveys under subds. 1. and 2.

AB68,1562,8 (9) Penalty. A manufacturer that fails to comply with this section may be assessed a penalty of up to $200,000 per month of noncompliance, with the maximum penalty increasing to $400,000 per month if the manufacturer continues to be in noncompliance after 6 months and increasing to $600,000 per month if the manufacturer continues to be in noncompliance after one year.

AB68,2969 Section 2969 . 632.869 of the statutes is created to read:

AB68,1562,11 632.869 Reimbursement to federal drug pricing program participants. (1) In this section:

AB68,1562,15 (a) “Covered entity” means an entity described in 42 USC 256b (a) (4) (A), (D), (E), (J), or (N) that participates in the federal drug pricing program under 42 USC 256b, a pharmacy of the entity, or a pharmacy contracted with the entity to dispense drugs purchased through the federal drug pricing program under 42 USC 256b.

AB68,1562,16 (b) “Pharmacy benefit manager” has the meaning given in s. 632.865 (1) (c).

AB68,1562,18 (2) Any person, including a pharmacy benefit manager and 3rd-party payer, may not do any of the following:

AB68,1562,21 (a) Reimburse a covered entity for a drug that is subject to an agreement under 42 USC 256b at a rate lower than that paid for the same drug to pharmacies that are not covered entities and are similar in prescription volume to the covered entity.

AB68,1562,24 (b) Assess a covered entity any fee, charge back, or other adjustment on the basis of the covered entity's participation in the federal drug pricing program under 42 USC 256b.

AB68,2970 Section 2970 . 632.87 (4) of the statutes is amended to read:

AB68,1563,5 632.87 (4) No policy, plan or contract may exclude coverage for diagnosis and treatment of a condition or complaint by a licensed dentist or dental therapist within the scope of the dentist's or dental therapist's license, if the policy, plan or contract covers diagnosis and treatment of the condition or complaint by another health care provider, as defined in s. 146.81 (1) (a) to (p).